The neurotransmitters and vasoactive substances regulating tone in the smooth muscle of the penile arteriesaarterioles and the trabeculae of the corpora cavernosa are critical mediators of the state of penile erection. Contemporary research reveals a coordinated, intricate interplay between the pathways of vasorelaxation and vasoconstriction representing a most ef®cient physiological mechanism to initiate and maintain penile erection. This paper will focus on the role of the adrenergic constrictor pathways in penile erection and, more speci®cally, on the pre-junctional adrenergic mechanisms that regulate smooth muscle constriction. All neurogenic constrictor responses are related to the release of norepinephrine from adrenergic nerves that act on postjunctional alpha-1 and pre-junctional and post-junctional alpha-2 receptor subtypes. Based on the current state of knowledge, there are at least three pre-junctional mechanisms regulating penile smooth muscle tone. First, norepinephrine release from the adrenergic nerves binds to the prejunctional alpha-2 adrenoceptor on the adrenergic nerves and negatively regulates norepinephrine release. Blockade of this reaction by selective alpha-2 receptor antagonists (e.g. yohimbine or delequamine) will enhance norepinephrine release. Second, norepinephrine release from the adrenergic nerves binds to the pre-junctional alpha-2 adrenoceptor on the non-adrenergic, noncholinergic (NANC) nerves and inhibits nitric oxide synthesis and release. Blockade of this reaction by selective alpha-2 receptor antagonists (e.g. yohimbine or delequamine) will enhance nitric oxide release, facilitating erection. Finally, cholinergic nerves pre-junctionally inhibit norepinephrine release from the adrenergic nerve and stimulate the NANC nerve to increase nitric oxide synthesis and release. These observations indicate that different neurotransmitters regulate the adrenergic neurotransmission pathway. Based on the above concepts for pre-junctional and post-junctional regulation of smooth muscle tone, the most ef®cacious strategy to reduce adrenergic activity and facilitate penile erection is to combine alpha-1 and alpha-2 adrenergic receptor antagonists. In this case, any enhancement of norepinephrine release is of little importance because the alpha-1 receptor antagonist will impede this vasoconstrictor response. This will also enhance the release of nitric oxide, which increases smooth muscle relaxation and decreases contraction resulting in penile erection.
Introduction
Penile erection is a neurovascular event which involves the regulation of in¯ow and out¯ow hemodynamics within the corpora cavernosa.
1±3
Locally, the state of penile erection is dependent on the tone of the arterial and trabecular penile smooth muscle. 1±5 There are two types of smooth muscle cells in erectile tissue. 1±5 One is the smooth muscle in the cavernosal and the helicine arteries, while the other is the smooth muscle in the trabeculae. These two types of smooth muscle cells are often considered the same, although, signi®cant differences exist in their responses to stimuli related to regulation of smooth muscle tone. The smooth muscle of the helicine arteries regulates arterial blood in¯ow and perfusion pressure from the systemic circulation to the lacunar spaces of the corpora cavernosa. 1, 2, 4 On the other hand, the trabecular smooth muscle comprises approximately 50% of the tissue content of the corpora cavernosa. Trabecular smooth muscle plays an important role in regulating the ability of the penis to expand during ®lling and to activate the corporal venoocclusive mechanism. 4, 5 In penile¯accidity, a state of high smooth muscle tone exists, particularly in the resistance helicine arteries. 1±5 In the contracted state, these arteries provide a large perfusion pressure gradient between the cavernosal artery (at systemic blood pressures) and the lacunar spaces (at systemic venous pressures). In¯accidity, this resistance produces limited pressure and blood¯ow delivered to the lacunar space. 4 Similarly, in¯accidity, the trabecular smooth muscle also has high tone, allowing the system that drains the penis to be in a decompressed state, so that any blood that enters into the lacunar space will exit unimpeded. 2 Upon sexual stimulation, smooth muscle relaxation and dilation of the arteries is associated with the development of high¯ow and high pressure into the lacunar space. 1, 2, 4 The relaxation of the trabecular muscle results in expansion of the penis and activation of the corporal veno-occlusive mechanism. Regulation of arterial and trabecular smooth muscle tone is complex and involves not only autonomic nerves that release constrictor or dilator neurotransmitters, but also endothelium-derived constrictor and dilator substances that diffuse to the underlying muscle and in¯uence smooth muscle tone.
1±3,6±8 Smooth muscle cells also synthesize some of these vasoactive substances which act through an autocrine mechanism and further in¯uence smooth muscle tone. In addition, circulating substances (growth factors, hormones, etc.) in blood may enter into the smooth muscle and in¯uence its tone. The key concept addressed in this discussion is a balance between the various vasoconstrictors and vasodilators mediating smooth muscle function.
3,9±11 Within this framework, physiologic and biochemical mediators that affect this delicate balance are critical for maintaining erectile function. Any imbalance favoring vasoconstriction as a consequence of aging, atherosclerotic vascular disease, diabetes mellitus, or various medications may result in erectile dysfunction.
3,9±11
Activation of the parasympathetic pathways, which involves the efferent motor autonomic nerves, the endothelium (in response to increased shear stress) and probably the smooth muscle (trabeculae), generates vasodilator substances which facilitate the relaxatory pathways and inhibit the release or activity of the constrictor pathways and lead to penile erection.
1±3,6,9,12±16 Similarly, the sympathetic pathways, which involve the efferent motor autonomic nerves, the endothelium and, probably the smooth muscle, generate vasoconstrictor substances, which facilitate the contractile pathways and inhibit the release or activity of the vasodilators during initiation and maintenance of accidity. 1±3,6 ,8±11 This coordination represents the most ef®cient mechanism to achieve and maintain erection.
Alpha-adrenergic activity in erectile function
This paper will focus on the role of the adrenergic constrictor pathways in penile erection and, more speci®cally, on the prejunctional adrenergic mechanisms which regulate smooth muscle contractility ( Figure 1 ). The contractile response is mediated by several vasoconstrictor catecholamines, either released by the adrenergic nerves or from the systemic circulation (adrenal medulla).
1±3,6,8±10 Other vasoconstrictor peptides, such as endothelins, are released by the endothelium or from the smooth muscle itself and are known to be potent constrictors of penile muscle tissue and augment the constriction response to adrenergic agonists. 1 Also, other vasocontrictor agents such as prostanoids (PGF2a and thromboxane A2), angiotensin and neuropeptide Y may have an important effect in in¯uencing smooth muscle contractility. 1 Norepinephrine is a potent constrictor of arterial and trabecular smooth muscle 1±3,6,8±10,17±28 In isolated penile resistance arteries or in isolated trabecular smooth muscle tissue strips, electrical stimulation of the autonomic nerves produces frequency-dependent constrictor responses. 17, 18 In penile arteries, as well as in the trabeculae, these responses are completely eliminated by treatment with pharmacological agents that interfere with adrenergic neurotransmission. 26, 27 It appears that all neurogenic constrictor responses are related to the release of norepinephrine from adrenergic nerves. Once norepinephrine is released, it acts on different alpha receptor subtypes.
22±25,28
Figure 1 Working hypothesis of activation of adrenergic neurotransmission in the penis. Norepinephrine (NE) binds to prejunctional alpha-2 adrenergic receptors (a2) inhibiting further norepinephrine release. Norepinephrine can also bind to alpha-1 or alpha-2, or beta-2 adrenergic receptors on the trabecular smooth muscle cells leading to either contraction or relaxation depending on the receptors present. Binding of norepinephrine to prejunctional alpha-2 adrenergic receptors on nonadrenergic, noncholinergic (NANC) nerves inhibits nitric oxide (NO) production which can further decrease trabecular smooth muscle relaxation. Epinephrine (E) can also bind to beta-2 adrenergic receptors on the trabecular smooth muscle cells leading to relaxation.
The contractions elicited by electrical stimulation are completely blocked by alpha-1 selective antagonists. Thus, upon electrical ®eld stimulation (EFS), we do not observe contributions from the alpha-2 component. The observed response may be explained by the hypothesis that there is a different cellular location of alpha-1 and alpha-2 adrenergic receptors on the smooth muscle cells and that the alpha-1 receptors may be in close proximity to the adrenergic nerve terminal. In contrast, the alpha-2 receptors on the smooth muscle are hypothesized to be localized away from the adrenergic nerve terminals. This may explain the poor inhibition of the contractile response with alpha-2 antagonists during electric ®eld stimulation. In any case, it appears that the principal constrictor mechanism, in the penis, is through alpha-1 receptors and a less physiologically important component are alpha-2 receptors in the smooth muscle.
Norepinephrine release and binding to postjunctional alpha-1 receptors initiates a cascade of events leading to increased intracellular calcium and increased contractility. Simultaneous measurements of intracellular free calcium and smooth muscle tone is one of the approaches used to test this hypothesis. In tissue strips of corpus cavernosum exposed to the alpha-1 adrenergic agonist phenylephrine, there is an increase in intracellular calcium, which then decreases and stabilizes to a threshold value above baseline. This is probably due to the release of calcium from intracellular stores following the depolarization phenomenon. 29 Administration of vasodilator agents, such as prostaglandin E1, reverses the smooth muscle contractile process. There are a host of mechanisms at the intracellular level that are activated either through the cyclic GMP or cyclic AMP pathway. The cyclic AMP pathway, via protein kinase A, probably causes a decrease in the sensitivity of the contractile proteins to intracellular calcium.
1±3
Under these conditions, the intracellular calcium concentration need not change for the contractile apparatus to become less sensitive to calcium and exhibit relaxation. But in addition to that, the cyclic GMP pathway through protein kinase G reduces intracellular calcium by internal sequestration into the sarcoplasmic reticulum or extrusion into the extracellular milieu. In addition to that, both protein kinase G and protein kinase A cause hyperpolarization, the opposite of the responses mediated by adrenergic stimulation. The ultimate response is the closing down of voltage sensitive calcium channels and reducing the amount of calcium that enters into the cell. Thus, in light of these complex and diverse mechanisms, there is a decrease in calcium in response to vasodilators, which is followed by decrease in tone.
Indeed the adrenergic system is important in regulating erection in humans. Men have three to ®ve erection episodes every night and these erection episodes are typically related to a rapid eye movement (REM) sleep phase. Coincident with the initiation of the parasympathetic phase, an erectile response ensues and this usually terminates when the parasympathetic phase is substituted by the sympathetic phase. There is a regulation through sympathetic±parasympathetic balance and it is recognized that sympathetic adrenergic activity is particularly important.
8±11 Furthermore, a hypothesis has been proposed that excessive adrenergicgenerated tone in aging may be an etiological factor for erectile dysfunction. 30 In addition to alpha-1 and alpha-2 adrenergic receptors, the trabecular smooth muscle expresses functional beta-2 adrenergic receptors. Thus, catecholamines interact with all these receptors modulating contractility. The state of smooth muscle contractility is a balance between contraction mediated by alpha-adrenergic receptors and relaxation mediated by beta-adrenergic receptors. In older men and in patients treated with beta blockers, alteration of beta-receptor function may tilt the balance towards contraction and this could heighten the adrenergic tone.
Pre-junctional modulation of alpha-adrenergic activity
Evidence from various studies suggests that attenuation of the adrenergic input into the penis may facilitate erection. Activation of the adrenergic neurotransmission not only causes release of norepinephrine that reaches post-junctional receptors Figure 2 Working hypothesis of prejunctional regulation of penile adrenergic nerves. Prejunctional beta-2 adrenergic receptors and thromboxane A2 receptors (TP) positively stimulate norepinephrine release while prostaglandin E (EP), alpha-2-adrenergic (a2), and muscarinic (M) receptors inhibit norepinephrine release in the presence of the appropriate ligand.
Presynaptic alpha adrenergic activity in corpus cavernosum I Saenz de Tejada et al localized to the smooth muscle, but also regulates the activity of the pre-synaptic adrenergic receptors modulating adrenergic and non-adrenergic nerves. 18±20,26,27 Adrenergic nerves, therefore, are regulated through feedback mechanisms via binding of released norepinephrine to the pre-junctional alpha-2 adrenergic receptors. In experiments in which norepinephrine release from adrenergic nerve terminals was measured in either rabbit or human corpus cavernosum tissue, treatment with alpha-2 adrenergic receptor antagonists induced a very large increase in norepinephrine release, suggesting pre-junctional modulation by alpha-2 adrenergic receptors (Figure 2) .
In penile arteries, electrical stimulation of the adrenergic nerves caused contractions. Alpha-1 receptor antagonists effectively block or reduce electrical ®eld stimulation-induced contractions. In contrast, alpha-2 adrenergic receptor antagonists produce minimal effects on the contractile response with some tendency to increase the contractile response. 26, 27 Despite the fact that alpha-2 adrenergic receptor antagonists are administered, an enhancement of the nerve-mediated contraction is observed. This is most likely due to the alpha-2 adrenergic receptor antagonist causing an increase in the release of norepinephrine through a prejunctional mechanism. In addition, yohimbine, an alpha-2 receptor antagonist, when given in a dose of 1 mg intracavernosally in the rabbit, often causes an initial fall in blood pressure followed by a signi®-cant increase as a result of release of norepinephrine from adrenergic nerve terminals.
Another mechanism regulating the adrenergic pathway occurs by release of acetylcholine from the cholinergic nerves. Released acetylcholine interacts with muscarinic acetylcholine receptors and modulates the adrenergic nerves. Electrical stimulation results in a dramatic reduction in norepinephrine release that is reversed by atropine. This demonstrates that pre-junctional muscarinic acetylcholine receptors are involved in regulation of norepinephrine release from the adrenergic nerve terminals. 12, 31 Prostanoids also pre-junctionally regulate norepinephrine release, in addition to alpha-2 receptors and to muscarinic receptors. In the presence of PGE1 or the active metabolite of PGE1, PGE0, we observe a signi®cant inhibition of norepinephrine release in response to electrical ®eld stimulation (unpublished observations). This inhibition is not observed with prostacyclin, probably because the action of prostanoids is mediated via an EP receptor subtype ( Figure 3 ).
These observations indicate that different receptors from different systems, acting via different neurotransmitter systems or substances which are produced locally are able to regulate the adrenergic neurotransmission pathway. There is evidence that adrenergic receptors may regulate other neuroeffector systems. The very important non-adrenergic, non-cholinergic (NANC) neuro-effector system, which releases nitric oxide, functionally antagonizes adrenergic activity and produces relaxation. It has been shown that alpha-2 adrenergic receptors and muscarinic receptors regulate the NANC neurotransmission and enhance nitric oxide release. 15, 26, 27 Since bretylium blocks adrenergic nerves, no adrenergic neurotransmission is detected in response to EFS in the presence of this agent. We electrically stimulated the non-adrenergic, noncholinergic nerves producing a relaxation response which is mediated by nitric oxide. Treatment of tissue with physostigmine, an acetylcholine esterase inhibitor, prolongs the half-life of acetylcholine and augments the response, particularly in duration and the overall response to the same nerve stimulation. Atropine completely reverses the relaxation response. We conclude from these studies that muscarinic acetylcholine receptors modulate the NANC stimulation. These studies suggest that indeed cholinergic nerves may regulate inhibition of norepinephrine release, through pre-junctional mechanisms, although this remains to be fully demonstrated. One explanation is that the release of NO may directly or indirectly modulate the adrenergic nerves. These observations support the concept of turning on and off different mechanisms, including the cholinergic mechanism which appears to be particularly important.
There is evidence that alpha-2 adrenergic receptors pre-junctionally regulate adrenergic response in erectile tissue. In horse penile arteries, Simonson and collaborators 26, 27 demonstrated that the release of NANC neurotransmitters, primarily thought to be NO, is inhibited by stimulation of pre-junctional alpha-2 adrenergic receptors in these penile organs. This may be an important coordinating mechanism for activating the adrenergic pathway in addition to inhibiting the non-adrenergic, non-cholinergic mechanism.
To put this into a general framework, we must consider the concepts for pre-junctional regulation, post-junctional regulation and the cellular distribution of adrenegic receptors. If one were to consider strategies to reduce adrenergic activity with different selective alpha-adrenergic antagonists, a highly selective alpha-1 adrenergic receptor antagonist would be important. This would block probably the major pathway that leads to adrenergically mediated contraction. This antagonist will not affect the contribution of alpha-2 adrenergic receptors on pre-or post-junctional regulation (Figure 4) . What happens if an alpha-2 adrenergic receptor blocker such as yohimbine or delequamine is used? We expect a reduction in contractility via alpha-2 adrenergic receptors. However, blocking alpha-2 adrenergic receptors increases norepinephrine release and this increase in the concentration of norepinephrine will result in interaction with alpha-1 receptors and actually increase contractility. This may be, in fact, one of the reasons why yohimbine or other selective alpha-2 adrenergic receptor antagonists that had been clinically utilized for the treatment of male erectile dysfunction have a limited ef®cacy due to an increase in norepinephrine release, favoring contraction. A bene®cial effect is that blocking the alpha-2 adrenoceptor enhances release of NO and increases relaxation. The increase in the relaxation is attenuated by the increase in contraction secondary to the augmented release of norepinephrine and its interaction with alpha-1 receptors ( Figure 5) .
A better strategy for ef®cacious treatment of male erectile dysfunction is to combine alpha-1 and alpha-2 adrenergic receptor antagonists ( Figure 6 ). Blockade of all constrictor post-junctional pathways attenuates adrenergic stimulation. Any enhancement Figure 4 Penile alpha-1 adrenergic receptor blockade. Blockade of the post-junctional (smooth muscle) alpha-1 adrenergic receptors by a selective antagonist leads to a decrease in the contractile response to norepinephrine (NE) and an enhancement of the relaxatory effects of nitric oxide (NO) and epinephrine (E) on the trabecular smooth muscle. Figure 5 Penile alpha-2 adrenergic receptor blockade. Blockade of both pre-and post-junctional alpha-2 adrenergic receptors by a selective antagonist leads to an increase in the contractile response due to release of norepinephrine which now interacts with the functional post-junctional alpha-1 adrenergic receptors on the smooth muscle. However, this is counterbalanced by increased NO release from NANC nerves which can lead to increased smooth muscle relaxation. Figure 6 Principles of combined penile alpha-1 and alpha-2 adrenergic receptor blockade. Blockade of the post-junctional (smooth muscle) alpha-1 adrenergic receptors by a selective antagonist as well as both pre-and post-junctional alpha-2 adrenergic receptors by a selective antagonist leads to a decrease in the contractile response to norepinephrine (NE) and an enhancement of the relaxatory effects of nitric oxide (NO) and epinephrine (E) on the trabecular smooth muscle.
of norepinephrine release is of little importance because alpha-1 adrenergic receptor antagonists will impede this vasoconstrictor response. This will also enhance the release of NO, which increases smooth muscle relaxation and decreases contraction resulting in penile erection. If one were to devise an effective therapeutic alternative, then one should modify NANC activity by combining alpha-1 and alpha-2 adrenergic receptor blockade and maximizing enhanced release of NO. This would be the most logical strategy. The implication of this strategy is that future therapy may employ combination drug therapy for treatment of erectile dysfunction.
